ASXL1 and myelodysplastic syndrome: To the best of our knowledge, this is the first study to provide real‐world data that clarify an adverse prognosis of ASXL1‐G646W mutations in patients with AML and MDS, which sheds light on a new perspective of prognostic risk factors in patients with ASXL1mt.